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1494In the PLATO (Platelet Inhibi-
tion and Patient Outcomes) trial
(NCT00391872), ticagrelor pre-
vented the composite of cardiovas-
cular death, myocardial infarction
(MI), and stroke compared with
clopidogrel in a broad acute cor-
onary syndromes (ACS) popula-
tion (hazard ratio [HR]: 0.84;
95% conﬁdence interval [CI]:
0.77 to 0.92; p < 0.001), without
increased risk of overall major
bleeding, but with a higher rate of
bleeding not related to coronary
artery bypass grafting (CABG)
(1,2). A reduction in MI was
observed with ticagrelor (HR:
0.84; 95% CI: 0.75 to 0.95;
p ¼ 0.005). A clinical events
committee (CEC) was used to
systematically identify and adju-dicate cause of death and all suspected MI and stroke events.
Our objective was to analyze the types of MI events, the
timing, and the treatment effects observed, as well as to
review the CEC process and describe the concordance
between the site investigator-reported MI events and the
CEC-adjudicated results.Methods
The PLATO trial design, patient population, study protocol
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ees from Sanoﬁ-Aventis, AstraZeneca, Bayerpreviously published (1,3). The protocol was approved by
national and institutional regulatory authorities and ethics
committees, and all patients provided written informed con-
sent. Patients with a new diagnosis of ACS randomly received
double-blind ticagrelor or clopidogrel for 6 to 12months. The
protocol speciﬁed maintenance treatment with open-label
aspirin, 75 to 100 mg/day, except when contraindicated or
not tolerated; this followed a single loading dose (160 to
500 mg allowed, 325 mg preferred) for those patients not
receiving aspirin just before randomization (4). After coro-
nary stent placement, the protocol allowed 325-mg/day
aspirin for 6 months (5). Decisions about coronary angi-
ography, revascularization procedures, and pharmacotherapy
were left to the discretion of the treating physician.
Events. Patients were followed after discharge from the
index hospitalization at 1, 3, 6, 9, and 12 months. Site
investigators were to report all suspected cardiac ischemic
events and characterize them as ST-segment elevation
myocardial infarction (STEMI), non–ST-segment elevation
myocardial infarction (NSTEMI), unstable angina, stable
angina, or other. The last scheduled visit was considered the
censoring event, and no endpoint events that occurred after
this visit were used in the analysis of the trial.
The CEC developed a comprehensive strategy to identify
all suspected deaths, cardiac ischemic events, strokes, and
bleeding events. The approach was documented in a separate
charter that was prepared by the academic leadership with
review and comments by the sponsors and the Executive
Committee. This report focused on the cardiac ischemic
events and the MI component of the primary endpoint. All
suspected MI events were identiﬁed by the following
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1495case report form; 2) cardiac biomarker data provided by the
site investigators on the case report form and from central
laboratories were evaluated for elevations consistent with an
MI or recurrent MI; and 3) a novel method was used to
evaluate trends in biomarker data during the index hospi-
talization to identify potential re-elevation in markers that
would suggest a potential MI requiring review by the CEC.
The relatively novel method involved 2 blinded physicians
independently reviewing plots of creatine kinase-MB (CK-
MB) and troponin values in relation to time of randomization,
revascularization procedures, and recurrent ischemic events,
with the aim of identifying patients with stable or falling
biomarkers before percutaneous coronary intervention (PCI)
or CABG and those with post-randomization CK-MB ele-
vations (6). The plots were based on a semi-logarithmic scale
that displayed biomarker values in 2 dimensions, with time
from randomization (in hours) provided on the X-axis (linear
scale) and biomarkers indexed by the upper limit of normal on
the Y-axis (logarithmic scale). Each plot was reviewed by
2 physicians (K.W.M., C.H.); if either physician indicated
that there was a potential re-elevation in biomarkers sugges-
tive of an endpoint event, the event was sent to the CEC for
adjudication. This task was performed by physicians rather
than a computer program because of the difﬁcult in-
terpretations posed by the complex relationships between
timing of symptoms, procedures, and biomarker release
patterns.
All suspected cardiac ischemic events were adjudicated
independently by 2 physicians. If the physicians agreed thatFigure 1 Suspected Events Identiﬁed by the Site Investigators and t
*Include events with ﬁnal diagnosis “Other” with text suggesting MI. **Include events with
MI. CEC ¼ clinical events committee; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segm
elevation myocardial infarction.an event did or did not occur, the event was considered
complete. If the physicians disagreed, the event was reviewed
by a committee of 3 physicians and a ﬁnal decision rendered.
The CEC personnel and the CEC physician reviewers were
blinded to the study drug assignment.
The deﬁnitions for MI and the PLATO classiﬁcation of
MI types are listed in Online Appendix A. For each MI
event that was adjudicated as meeting endpoint criteria, the
physicians recorded type of MI according to the following:
nonprocedural, within 24 h after PCI, within 24 h after
CABG, MI resulting in death before cardiac markers
ascertainment, silent MI, STEMI, NSTEMI, unknown
STEMI/NSTEMI, or Q-wave, non–Q-wave, or Q-wave
status not evaluable. MI events were categorized post-hoc on
the basis of the universal MI deﬁnition from 2007 (7) before
the revised deﬁnition published in 2012 (8) as either: 1) all
MIs not associated with PCI, CABG, stent thrombosis, or
death; 2) MI associated with death; 3) MI associated with
PCI; 4) MI associated with stent thrombosis; or 5) MI
associated with CABG.
Statistical analysis. Categorical variables are summarized
as frequencies and percentages, and continuous variables as
medians and quartiles. HRs comparing randomized treat-
ments (ticagrelor vs. clopidogrel) were derived from Cox
proportional hazards models. Competing risk of death was
accounted for by censoring patients at time of death.
All exploratory analyses used SAS software (version 9.2,
SAS Institute, Cary, North Carolina) and report nominal
signiﬁcance levels without adjustment for multiplicity.he CEC in PLATO
ﬁnal diagnosis “Unstable Angina”, “Stable Angina”, and “Other” with text suggesting
ent elevation myocardial infarction; PI ¼ principal investigator; STEMI ¼ ST-segment
Figure 2 MI Events by Treatment Reported by the CEC
Abbreviations as in Figure 1.
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1496Results
A total of 5,447 events were identiﬁed as potential MI events
using the comprehensive processes described and processed
through the CEC for adjudication. Of the 5,447 events,
2,705 (49.7%) were identiﬁed by the site investigator asTable 1 Treatment Effect by Type of MI as Classiﬁ
Type of MI
No. of
Events*
No. of
Ticag
Classiﬁed by CECy 1,097 50
STEMI 275 11
NSTEMI 760 35
Not evaluable 92 4
Q-wave 77 3
Non–Q-wave 708 33
Q-wave not evaluable 368 16
Nonprocedure related 652 30
Procedure-related 304 14
PCI-related 223 9
CABG-related 82 4
Associated with stent thrombosis 172 6
Classiﬁed by site investigator 975 45
STEMI 352 15
NSTEMI 594 28
Other 60 2
Values are n or hazard ratios (95% CIs). *Number of events of each type. For pat
Patients can have events of more than 1 type and be counted in multiple row
CABG ¼ coronary artery bypass graft; CEC ¼ clinical events committee; C
NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutan
infarction.cardiac ischemic events (Fig. 1): 1,198 (44%) were reported
as MI events by the site investigators, and 1,507 (56%) as
various cardiovascular events that could potentially have been
anMI. The remaining 2,742 (50.3%) of the 5,447 events were
identiﬁed by other mechanisms, including a computer algo-
rithm, reviews of electrocardiograms, and plot reviews. From
these 2,742 events, an additional 251 events not reported by
the site investigator were reported by the CEC as MI events.
Overall, of the 5,447 events adjudicated by the CEC,
1,299 MI events were reported to have occurred by the CEC
(610 ticagrelor, 689 clopidogrel). Of these 1,299 MI events,
1,288 were nonsilent MIs, and 1,232 were nonsilent MIs
between randomization and the end of the study (Fig. 2).
Finally, after removing multiple MIs in some patients, a
total of 1,097 patients with nonsilent MIs (504 ticagrelor,
593 clopidogrel) were available for analyses of the MI
endpoint. Figure 2 shows the reasons why the 202 (1,299 
1,097) MI events were excluded from the MI analyses for
efﬁcacy. For the 52 MIs reported after the end-of-study
censoring date occurred, the median (quartiles) for the
number of days after censoring was 14 (9, 25): 15 (8, 26) for
ticagrelor (n ¼ 37) and 13 (9, 23) for clopidogrel (n ¼ 15).
Table 1 shows the treatment effect by type of MI for the
ﬁrst MI event for each patient reported by the CEC. The
most common MI type was nonprocedural. Ticagrelor
signiﬁcantly reduced overall 12-month Kaplan-Meier MI
rates (5.8% ticagrelor, 6.9% clopidogrel; HR: 0.84; 95% CI:
0.75 to 0.95; p ¼ 0.005). The direction of the treatment
effects was consistent across the MI types except for CABG-
related, but there were few of these events, and CIs were
wide. Figure 3 shows the Kaplan-Meier curves by MI type
and treatment. The treatment effects were observed early
and maintained over time. Table 1 also shows the treatmented by the CEC or Site Investigator
Events:
relor
No. of Events:
Clopidogrel
HR (95% CI)
Ticagrelor vs. Clopidogrel
4 593 0.84 (0.75–0.95)
7 158 0.74 (0.58–0.94)
6 404 0.88 (0.76–1.01)
0 52 0.77 (0.51–1.16)
7 40 0.92 (0.59–1.44)
3 375 0.88 (0.76–1.02)
0 208 0.76 (0.62–0.94)
3 349 0.86 (0.74–1.01)
4 160 0.90 (0.72–1.12)
9 124 0.79 (0.61–1.03)
5 37 1.21 (0.78–1.87)
9 103 0.67 (0.49–0.90)
9 516 0.88 (0.78–1.00)
6 196 0.79 (0.64–0.98)
7 307 0.93 (0.79–1.09)
9 31 0.93 (0.56–1.55)
ients with multiple events of the same type, only the ﬁrst event is counted.
s. yExcluding silent MIs.
I ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction;
eous coronary intervention; STEMI ¼ ST-segment elevation myocardial
Figure 3 Treatment Effect by Type of MI
CABG ¼ coronary artery bypass graft; HR ¼ hazard ratio; MI ¼ myocardial infarc-
tion; PCI ¼ percutaneous coronary intervention.
Figure 5 Disagreements Between CEC and Site Investigators
Abbreviations as in Figure 1.
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1497effect for MIs deﬁned by the presence or absence of
ST-segment elevation or Q-waves as reported by the CEC.
Site investigators reported a total of 1,198 MIs (580
ticagrelor, 618 clopidogrel) with 1,128 of them between
randomization and end of the study. Overall, there were
more CEC-adjudicated MIs (1,299) than site investigator-
reported MIs (1,198). Figure 4 shows the proportion of
CEC-adjudicated MIs and site investigator-reported MIs
that were nonprocedural, PCI-related, or CABG-related.
Table 1 shows the treatment effect by type of MI reported
by the site investigator. The treatment effects with ticagrelor
compared with clopidogrel were consistent compared with
the same classiﬁcations reported by the CEC, although for
total MIs, the 95% CI crossed 1.0.
Concordance between the CEC and site investigators was
explored at the patient level. In this analysis, patients wereFigure 4 Breakdown of CEC-Adjudicated MIs and Site Investigator-R
Abbreviations as in Figures 1 and 3.classiﬁed as having or not having an MI between randomi-
zation and the end of the study on the basis of the CEC and
site investigator information. Overall, the CEC and the site
investigators agreed that 17,277 patients did not have an MI
event, and that 725 patients had an MI event, for a 96.7%
agreement (Table 2). Of the patients with an MI determined
by theCEC (n¼ 1,097), the site investigators reported that an
MI occurred for 725 (66.1%). For those patients for whom the
site investigator reported an MI, the CEC conﬁrmed an MI
for 74.4%. Overall, the CEC identiﬁed 184 MIs in the tica-
grelor patients and 188 MIs in the clopidogrel patients not
reported by the site investigators (Fig. 5). Likewise, for
events reported by the site investigators that were not
conﬁrmed to meet study criteria for anMI by the CEC, thereeported MIs
Table 2 Comparisons: CEC and Site Investigator
Investigator Reported
CEC
Yes No Total
Yes 725 250 975
No 372 17,277 17,649
Total 1,097 17,527 18,624
Values are n. Using the ﬁrst event for patients with multiple events reported or adjudicated.
Abbreviation as in Table 1.
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1498were 139 MIs in the ticagrelor arm and 111 MIs in the clo-
pidogrel arm. Table 3 shows the MI types.
A total of 2,626 plots were generated, and 2,622 with
sufﬁcient data were processed and reviewed by 2 physicians as
planned. Of the 2,622, 284 (10.8%) were identiﬁed by at
least 1 of the 2 physicians as requiring adjudication by the
CEC. Of the 284 that went to formal adjudication, the CEC
called 59 (20.8%) an MI and 225 (79.2%) not an MI. Of
those called an MI, 26 were in the ticagrelor arm and 31 were
in the clopidogrel arm (HR: 0.92; 95% CI: 0.55 to 1.54).Discussion
In the PLATO trial, ticagrelor signiﬁcantly reduced the risk
of subsequent MI (1). These analyses show a consistency of
this treatment beneﬁt in reducing each of the different
MI types, including nonprocedural (e.g., spontaneous) and
PCI-relatedMI events, and those deﬁned by more traditional
methods, such as presence or absence of Q-waves or ST-
segment elevation. In addition, site investigators reported
fewer MI events compared with the CEC, but analyses of
treatment effects using site investigator-reported or CEC-
reported MIs were similar; however, with more events, the
ﬁndings were more statistically robust with the CEC data.Table 3 Description of CEC-Adjudicated MIs
Reported by PI on CIE Form
as STEMI/NSTEMI
(n ¼ 862)
Final diagnosis by PI
STEMI 285 (33%)
NSTEMI 554 (64%)
Unstable angina d
Stable angina d
Other 23 (3%)
Missing d
Final diagnosis by CEC
STEMI 266 (31%)
NSTEMI 549 (64%)
Not evaluable 47 (5%)
Q-wave 66 (8%)
Non–Q-wave 500 (58%)
Q-wave not evaluable 296 (34%)
Values are n (%).
CIE ¼ cardiac ischemic events; PI ¼ principal investigator; other abbreviatioRecurrent MI following ACS remains a common event
despite improvement in therapies in the past decade. In
PLATO, 1,299 MI events occurred during a median of 9
months of follow-up with continued accrual over time. The
use of continuous dual antiplatelet therapy with ticagrelor and
aspirin showed robust effects early with evidence of continued
accrual of beneﬁt over time. Signiﬁcant reduction in non-
procedural endpoint MIs was observed. The PCI-related
MIs occurred early, with a reduction in the hazard of MI
with ticagrelor similar to the overall MI hazard reduction
(0.794 vs. 0.840). The number of CABG MIs was small (45
ticagrelor, 37 clopidogrel), with a higher number seen with
ticagrelor compared with clopidogrel, but with a broad CI.
Site investigators reported fewer MIs than the CEC. This
is consistent with previous experiences (9,10). In PLATO,
the treatment beneﬁt observed with ticagrelor compared with
clopidogrel on MI was similar using the site investigator-
reported or the CEC-reported MI events. Some previous
trials have reported differences in trial outcomes when using
theCEC-reported events comparedwith the site investigator-
reported events (11), and the reasons are not clear. In
PLATO, the proportion of MIs reported by the site inves-
tigators as nonprocedural was higher than the proportion re-
ported by the CEC. This is consistent with previous ﬁndings
and reﬂects an underreporting of these events likely due to a
reluctance to report events that occur from a procedure being
performed, or in some situations, a lack of agreement with the
deﬁnition used or lack of awareness. The novel approach to
review plots of cardiac biomarker information integrated with
the clinical details identiﬁed 54 MIs not reported by the site
investigators. This was an efﬁcient strategy to identify early
events in patients who predominantly had elevated biomarkers
and earlier procedures. A similar approach has been used
successfully in other programs by the same CEC group (6).All CEC-Adjudicated MIs
(n ¼ 1,299)
Reported by PI on CIE Form But
Not as STEMI/NSTEMI
(n ¼ 186)
Not Reported
by PI on CIE Form
(n ¼ 251)
d d
d d
122 (66%) d
7 (4%) d
56 (30%) d
1 (< 1%) d
27 (15%) 11 (4%)
138 (74%) 198 (79%)
21 (11%) 42 (17%)
8 (4%) 20 (8%)
100 (54%) 193 (77%)
78 (42%) 38 (15%)
ns as in Tables 1 and 2.
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1499The recently revised universal MI deﬁnition (8) has
increased the threshold to diagnose a procedural MI by
increasing the CK-MB or troponin elevations that must be
obtained, but also includes additional criteria, such as is-
chemic symptoms and angiographic imaging, or electrocar-
diographic evidence of complications or infarction. We did
not collect these data in PLATO and, thus, could not perform
additional analyses on MI outcomes and treatment effects
using the revised universal deﬁnitions.
A recent report (12) using data published in the literature
or reported by the Food and Drug Administration in public
documents (13) was critical of the CEC processes used in
PLATO and other trials. The investigators insinuated im-
propriety in trial conduct because they concluded from the
available data that adjudicated events were added only to the
clopidogrel arm by the CEC. Our analyses, performed using
the raw data sets, clearly show the ﬂaw in the methodology
used by these investigators. Events were identiﬁed by the
CEC in both study arms that were not reported by the site
investigator, and the CEC did not agree with all site
investigator assessments on events in both study arms.
Study limitations. The trial was not powered to detect
treatment differences in the subtypes of MI using various
common reporting categories. We did not collect the MI
classiﬁcation by the site investigator using the universal MI
deﬁnition, but used the commonly used STEMI and
NSTEMI categorizations. Work such as the Food and Drug
Administration Standardized Data Collection for Cardio-
vascular Trials Initiative is a step in the right direction to
standardize systematic deﬁning and reporting ofMI endpoints
(14). Finally, we were unable to fully characterize the reasons
for disagreement between the CEC and site investigators,
which limited our ability to understand and recommend how
sites should report events for future trials.
Conclusions
In patients with ACS, ticagrelor signiﬁcantly reduced MI
compared with clopidogrel, with consistent results across
most MI subtypes. CEC procedures identiﬁed more MI
endpoints compared with site investigators. Understanding
CEC processes and concordance between the site investi-
gator and CEC are important to fully interpret trial results.
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APPENDIX
For supplemental material regarding the deﬁnitions for MI and the PLATO
classiﬁcation of MI types, please see the online version of this article.
